Digital Therapeutic (DTx) Market worth $6.9 billion by 2025 – Exclusive Report by MarketsandMarkets™

According to the new market research report " Digital Therapeutic (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global forecasts to 2025, published by MarketsandMarkets™, The global digital therapeutics market is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period (2020–2025).

Access Free Sample Research Copy : https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

                       

The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance.

On the other hand, a lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, unstable payment models, and resistance from traditional healthcare providers are challenging the growth of this market to a certain extent.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

What Drives the Market?

1 Increasing incidence of preventable chronic diseases
2 Rising focus on preventive healthcare
3 Need to control healthcare costs
4 Significant increase in venture capital investments

Global Market Segmentation:

Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). In 2019, the B2B segment accounted for the largest market share; it is also expected to grow at the highest CAGR of the digital therapeutics market.

Based on the type of buyer, the B2C sales channel market is further segmented into patients and caregivers. The caregivers segment is expected to dominate the market and register the highest CAGR during the forecast period.

Based on the application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. One of the key factors driving the growth of this segment is the rise in treatment and healthcare costs, especially due to chronic conditions.

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724

Key Players and Strategies Adopted by Them:

The digital therapeutics market is fragmented in nature, with a large number of players, including tier 1 and mid-tier companies competing for market shares. The prominent players in the global digital therapeutics market include Noom (US), Livongo Health (US), Omada Health (US), WellDoc (US), Pear Therapeutics (US), Proteus Digital Health (US), Propeller Health (US), Akili Interactive Labs (US), Better Therapeutics (US), Happify (US), Kaia Health (Germany), Mango Health (US), Click Therapeutics (US), Canary Health (US), Wellthy Therapeutics (India), Cognoa (US), Ayogo Health (Canada), Mindstrong Health (US), 2Morrow (US), and Ginger (US).

Digital Therapeutics Market Trends to 2021 "Driven by Healthcare IT companies"

 According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Access Free Sample Research Copy :https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

         

What Drives the Market?

1. Increasing Incidence of Preventable Chronic Diseases
2. Rising Focus on Preventive Healthcare
3. Technological Advancements
4. Need to Control Healthcare Costs
5. Significant Increase in Venture Capital Investments
6. Benefits Offered By Digital Therapeutics

The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

Global Market Segmentation:

Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.

Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.

Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.

Key Players and Strategies Adopted by Them:

Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)

Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724

Digital Therapeutics Market To Make Great Impact In Coming Future By Upcoming Innovations and Demand

The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.

According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

                    

The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.

According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.

Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.

Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.

Ask for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

Geographical Growth Analysis:

The digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period.

Key Players and Strategies Adopted by Them:

Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)
The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.

Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.

Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.

Ask for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

Geographical Growth Analysis:
The digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period.

Key Players and Strategies Adopted by Them:

Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)

Emerging trends in Digital Therapeutics Market by type, revenue, industry growth and forecast 2021

 The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724



The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.

Global Market Segmentation:
Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.

Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.

Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

What Drives the Market?

1. Increasing Incidence of Preventable Chronic Diseases
2. Rising Focus on Preventive Healthcare
3. Technological Advancements
4. Need to Control Healthcare Costs
5. Significant Increase in Venture Capital Investments
6. Benefits Offered By Digital Therapeutics

Geographical Growth Analysis:

The digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period.

Key Players and Strategies Adopted by Them:

Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)

Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724

Emerging trends in Digital Therapeutics Market by type, revenue, industry growth and forecast 2021

The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=51646724

The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms.

Global Market Segmentation:

Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product.

Based on sales channel, the digital therapeutics market is segmented into business to customer (B2C) and business to business (B2B). In 2016, the B2B segment is estimated to account for the largest share along with the highest CAGR of the digital therapeutics market. There is a growing awareness among providers, payers, and employers about the benefits provided by digital therapeutics, and the amount of healthcare cost reductions achieved by their use.

Additionally, there is a growing inclination of pharmaceutical companies to integrate digital therapeutics with their drug product to offer adherence services along with their product. These are some of the factors responsible for the high share of this market segment.

Get Expert Analysis and Insights of Global Market | Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=51646724

What Drives the Market?

1. Increasing Incidence of Preventable Chronic Diseases
2. Rising Focus on Preventive Healthcare
3. Technological Advancements
4. Need to Control Healthcare Costs
5. Significant Increase in Venture Capital Investments
6. Benefits Offered By Digital Therapeutics

Geographical Growth Analysis:

The digital therapeutics market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). In 2016, the North America is expected to dominate the market, followed by Europe. The market in North America is expected to grow at the highest CAGR during the forecast period.

Key Players and Strategies Adopted by Them:

Proteus Digital Health, Inc. (U.S.), Omada Health Inc. (U.S.), WellDoc Inc. (U.S.), Livongo Health (U.S.), Noom Inc. (U.S.), Ginger.io Inc. (U.S.), Propeller Health (U.S.), 2Morrow Inc. (U.S.), Canary Health Inc. (U.S.), Mango Health, Inc. (U.S.), and Physitrack Limited (U.K.). Click Therapeutics, Inc. (U.S.), Pear Therapeutics, Inc., (U.S.), Akili Interactive Labs, Inc. (U.S.) and Wellthy Therapeutics Pvt. Ltd (India)

Speak to Analyst @https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=51646724

Digital Therapeutics Market Industry Analysis, Size, Share, Growth, Trends and Forecast

According to the new market research report " Digital Therapeutics Market by Application (Prevention (Prediabetes, Obesity), Care (Diabetes, CVD, CNS, CRD, Smoking Cessation, Musculoskeletal)), Sales Channel (B2C (Patient, Caregiver), B2B (Provider, Payer, Employer, Pharma)) - Global Forecast to 2021", published by MarketsandMarkets™, The global digital therapeutics market is expected to reach USD 457.9 Million by 2021 from USD 110 Million in 2016, growing at a CAGR of 27.7% from 2016 to 2021.

Get Sample Copy for more Professional and Technical insights at : https://www.marketsandmarkets.com/ResearchInsight/digital-therapeutics-market.asp

The factors driving market growth include growing incidence of chronic diseases, rising focus on preventive healthcare, technological advancements, growing need to control healthcare costs, significant increase in venture capital investments, and the benefits of digital therapeutics. However, factors such as lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, and resistance from traditional healthcare providers may restrain the digital therapeutics market growth.

Browse and in-depth TOC on "Digital Therapeutics Market"

148  - Tables

36  - Figures

 Order a copy of “Digital Therapeutics Market Size & Share | Industry Analysis” research study at:

https://www.marketsandmarkets.com/PressReleases/digital-therapeutics.asp

The digital therapeutics market is highly fragmented, diversified, and increasingly competitive, with a large number of small players competing for market space, including startup firms. Each segment has different market players and market leaders. For instance, the prediabetes market was led by Omada in 2015. Omada Health is a leading provider of digital therapeutics for preventable type 2 diabetes and heart disease. Omada’s product portfolio consists of ‘Prevent’, an online diabetes prevention program. The company has succeeded in securing heavy investments which it channelizes into the development, enhancement, and commercialization of its product. 

Make an Inquiry Prior To Purchase this research study at: https://www.marketsandmarkets.com/Market-Reports/digital-therapeutics-market-51646724.html